Research Reference
Desmopressin
FDA-approved vasopressin analog for diabetes insipidus
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Desmopressin (DDAVP) is an FDA-approved synthetic vasopressin analog used for diabetes insipidus and certain bleeding disorders.
Dosing Reference
Reconstitution
Add 10 mL bacteriostatic water to the 0.01 mg vial. Resulting concentration: 0 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 4 mcg | 400 units | 4 mL | SubQ, dailyInjectable (FDA, hospital) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Desmopressin (DDAVP, Stimate, Minirin) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and von Willebrand disease/hemophilia A. It is supplied as an intranasal spray, oral tablet, or injectable — not user-reconstituted from lyophilized powder. Compounded research-peptide forms are not FDA-approved.
For compounded forms, concentration depends on vial size and diluent volume; no standard compounded protocol exists. Compounded forms are not FDA-approved.
Cycling Protocol
FDA-approved desmopressin is used as chronic therapy (intranasal, oral, or injectable) for the indicated condition; dosing is individualized to response. No fixed cycle end.
Routes of Administration
Subcutaneous (FDA-approved): Hospital use for von Willebrand disease / hemophilia A.
Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | DI management | Desmopressin + fluid management | Standard central DI protocol (FDA) |
Desmopressin is managed under specialist endocrinology/hematology supervision. Compounded forms are not FDA-approved.
Side Effects & Safety
- Hyponatremia — most significant risk; can be severe; fluid restriction guidance essential
- Headache, nausea — common
- Nasal congestion / irritation — common with intranasal
- Water intoxication — risk, especially in children/elderly; manage fluid intake
- Allergic reactions — rare
Desmopressin (DDAVP/Stimate/Minirin) is FDA-approved for central DI, nocturnal enuresis, and von Willebrand disease/hemophilia A. Compounded research-peptide forms are not FDA-approved.
Research Basis
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of antidiuretic hormone (vasopressin), FDA-approved.
Mechanism: Agonizes V2 vasopressin receptors in the kidney to increase water reabsorption (antidiuretic effect) without the pressor (V1) activity of natural vasopressin; also stimulates endothelial release of von Willebrand factor and factor VIII.
Clinical evidence: FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and von Willebrand disease/mild hemophilia A. Extensive clinical experience.
FDA-approved for the indications above. Compounded research-peptide forms are not FDA-approved.